Turtlespeed, you echoed what my views are, we are on the same page. If they cant get 3 or 4 more enrollments at least by years end I agree with you, do the trials in another country where likelihood of enrollments is much better. Even if it costs more. We can still get R&D grants even if trials are done elsewhere, it happens with some other ASX listed biotechs.
Steady decline, page-51
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
